Navigation Links
ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
Date:12/4/2012

PARIS, December 4, 2012 /PRNewswire/ --

ObeTherapy, a company focusing on the treatment of obesity and type II diabetes,  announces the publication of results that validate a new therapeutic target associated with  "starvation" human phenotype and a novel small-molecule candidate for the treatment of obesity and type II diabetes,

The article, entitled: Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatment, http://dx.plos.org/10.1371/journal.pone.0049612, Numerous genes associated with obesity have been targeted over the years to treat such a condition. However, none of these has provided an effective treatment for either obesity or type II diabetes.  Many commercial drugs that target such genes have been withdrawn from the market on accounts of lack of efficacy, lack of specificity, and/or toxicity. It is therefore essential to identify new gene targets that are specific, non-redundant and associated to lean phenotype.  

Research at ObeTherapy aims to identify genes that are implicated in a "lean" human phenotype by addressing the following questions:  Are there any genetic diseases that produce a "lean phenotype"? If so, is such a condition dependent upon a single gene (i.e., is it a monogenic disease)? Is such a gene tissue-specific? Is it redundant?

Congenital enteropeptidase deficiency is an extremely rare pathology that satisfies the foregoing criteria.  Patients suffering from such a condition can eat ad libitum without gaining weight; indeed, if left untreated, they will lose weight and ultimately starve (starvation phenotype).  Thus, partial inhibition of enteropeptidase with an approriate drug should allow obese patients to nourish themselves normally, yet assimilate only a fraction of the total energy consumed during a meal. These patients would thus retain the plea
'/>"/>

SOURCE ObeTherapy Biotechnology
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Semafore Pharmaceuticals Inc.,announced today on the occasion of ... Conference in San Francisco that its,integrin-targeted PI3 kinase ... agents in vitro and in vivo (poster,C207). ... of prostate cancer cells with combinations of docetaxel ...
... IRVINE, Calif., Oct. 26 IDM Pharma, Inc.,(Nasdaq: ... the development of,innovative cancer therapies, today announced details ... pipeline compounds to be,presented at upcoming medical congresses. ... Mifamurtide (L-MTP-PE):, Connective Tissue Oncology Society (CTOS) ...
Cached Medicine Technology:Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents 2IDM Pharma Announces Upcoming Clinical Data Presentations 2IDM Pharma Announces Upcoming Clinical Data Presentations 3IDM Pharma Announces Upcoming Clinical Data Presentations 4
(Date:7/10/2014)... July 10, 2014 One week ahead ... Worker Safety announced today it will extend compensation benefits ... months’ wages for workers displaced as a result of ... Alliance inspections have resulted in the closure of five ... five cases, raising immediate safety concerns. In May, the ...
(Date:7/10/2014)... 2014 According to a new ... Platforms (Land, Airborne, Naval), Application (Software Defined Radios, ... Geography (North America, Asia-Pacific, Europe, the Middle East ... by MarketsandMarkets, the market is estimated to be ... register a CAGR of 5.56% to reach $39.52 ...
(Date:7/10/2014)... In his latest blog post at http://www.perwickstrom.com , ... Wickstrom has listed 5 ways to follow-up without being ... get information or sometimes even just return an inquiry, ... a skill that most people don’t have,” commented Per ... dialogue moving without coming across as annoying – let ...
(Date:7/10/2014)... Creek, MI (PRWEB) July 10, 2014 ... alcohol treatment program that gets clients off to a ... recovery they can believe in, has launched a new ... , The new section highlights:, , ... Diagnostic and Statistic Manual of Mental Disorders (DSM-IV), including ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Ivalua, ... latest results of the 4th “Trending in Procurement” ... model. , Every day multinational corporations process ... expense forms etc. To meet this challenge, more ... suites which can be defined as a suite ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3
... Hospitality Solutions with Pro:Idiom , Enable MSOs to ... R.L. Drake , an American ... highly innovative communications solutions for over 65 years, has ... cable transcoders to cable operators in the United States ...
... April 1, GlaxoSmithKline (NYSE: GSK ... regulatory applications to expand the use of TYVERB(R)/TYKERB(R) ... as a first-line therapy regimen combined with anti-hormonal ... breast cancer in Europe and the United States.The ...
... low-level shoulder separations can commonly be treated nonsurgically and ... in the April 2009 issue of the Journal ... JAAOS ) finds that many surgeons still disagree on ... fall in between. , , Shoulder separations, clinically ...
... an important contribution to future clinical therapeutic approaches. The ... Nature and will be a central topic of ... which will take place in Munich from April 2nd ... mechanisms of blood formation (hematopoiesis) will be presented in ...
... Organization for disAbilities Resources champions company,s effortsGAITHERSBURG, Md., ... Disability Matters Award in the category of Work ... supporting people with disabilities and their families. The ... and Springboard Consulting. The integrated food and facilities ...
... mid-level, common injury ROSEMONT, Ill., April 1 While low-level shoulder ... surgery, a literature review published in the April 2009 issue of ... ( JAAOS ) finds that many surgeons still disagree ... in between., , ...
Cached Medicine News:Health News:Drake Nabs 'Suite Deal' as Distributor of Pro:Idiom(R) Hospitality Solution to U.S. and Canadian Cable Operators 2Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 2Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 3Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 4Health News:GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US 5Health News:Healing a shoulder separation 2Health News:Last step leading to blood cell formation elucidated 2Health News:Sodexo Receives 2009 Disability Matters Award 2Health News:Sodexo Receives 2009 Disability Matters Award 3Health News:Healing a Shoulder Separation 2Health News:Healing a Shoulder Separation 3
... lab with the OLA2500 High Speed Sorter ... sorting requirements. As a front-end sample-processor, the ... primary sample tubes to their destination racks ... eliminate sample-handling errors. Post-analytical archiving to any ...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Medicine Products: